Temelimab

Temelimab (also known as GNbAC1^[1]) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.^[2]^[3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions.^[1] As of 2023, it is also being studied for cognitive impairment in long COVID.^[4]

Quick Facts Monoclonal antibody, Type ...

References